6 September 2021 - The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and the sixth approved CAR-T product globally.

JW Therapeutics announced that the National Medical Products Administration of China has approved the new drug application for its anti-CD19 autologous chimeric antigen receptor T-cell immunotherapy product relmacabtagene autoleucel injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and has released the drug registration certificate.

Read JW Therapeutics press release